CD8A and neoplasm: In summary, data from our flow cytometry and scRNA-Seq analyses demonstrate that TREM1 inhibition alters the tumor immune landscape to limit MDSC frequency while boosting effector CD8+ T cell immunity to effectively augment PD-1 ICB therapy.